Literature DB >> 32755410

Pregnancy Protects Hyperandrogenemic Female Rats From Postmenopausal Hypertension.

Noha M Shawky1,2, Chetan N Patil3, Carolina Dalmasso4, Rodrigo O Maranon5, Damian G Romero1,2, Heather Drummond1,6, Jane F Reckelhoff1,2.   

Abstract

Polycystic ovary syndrome, the most common endocrine disorder in women of reproductive age, is characterized by hyperandrogenemia, obesity, insulin resistance, and elevated blood pressure. However, few studies have focused on the consequences of pregnancy on postmenopausal cardiovascular disease and hypertension in polycystic ovary syndrome women. In hyperandrogenemic female (HAF) rats, the hypothesis was tested that previous pregnancy protects against age-related hypertension. Rats were implanted with dihydrotestosterone (7.5 mg/90 days, beginning at 4 weeks and continued throughout life) or placebo pellets (controls), became pregnant at 10 to 15 weeks, and pups were weaned at postnatal day 21. Dams and virgins were then aged to 10 months (still estrous cycling) or 16 months (postcycling). Although numbers of offspring per litter were similar for HAF and control dams, birth weights were lower in HAF offspring. At 10 months of age, there were no differences in blood pressure, proteinuria, nitrate/nitrite excretion, or body composition in previously pregnant HAF versus virgin HAF. However, by 16 months of age, despite no differences in dihydrotestosterone, fat mass/or lean mass/body weight, previously pregnant HAF had significantly lower blood pressure and proteinuria, higher nitrate/nitrite excretion, with increased intrarenal mRNA expression of endothelin B receptor and eNOS (endothelial nitric oxide synthase), and decreased ACE (angiotensin-converting enzyme), AT1aR (angiotensin 1a receptor), and endothelin A receptor than virgin HAF. Thus, pregnancy protects HAF rats against age-related hypertension, and the mechanism(s) may be due to differential regulation of the nitric oxide, endothelin, and renin-angiotensin systems. These data suggest that polycystic ovary syndrome women who have experienced uncomplicated pregnancy may be protected from postmenopausal hypertension.

Entities:  

Keywords:  aging; endothelin; menopause; nitric oxide; renin-angiotensin system

Mesh:

Substances:

Year:  2020        PMID: 32755410      PMCID: PMC7429272          DOI: 10.1161/HYPERTENSIONAHA.120.15504

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  45 in total

1.  The role of plasma renin activity in distinguishing patients with polycystic ovary syndrome (PCOS) from oligomenorrheic patients without PCOS.

Authors:  G Uncu; M C Sözer; O Develioğlu; C Cengiz
Journal:  Gynecol Endocrinol       Date:  2002-12       Impact factor: 2.260

2.  Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension.

Authors:  B T Alexander; K L Cockrell; A N Rinewalt; J N Herrington; J P Granger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-05       Impact factor: 3.619

3.  Roles for the sympathetic nervous system, renal nerves, and CNS melanocortin-4 receptor in the elevated blood pressure in hyperandrogenemic female rats.

Authors:  Rodrigo Maranon; Roberta Lima; Frank T Spradley; Jussara M do Carmo; Howei Zhang; Andrew D Smith; Elizabeth Bui; R Lucas Thomas; Mohadetheh Moulana; John E Hall; Joey P Granger; Jane F Reckelhoff
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-02-18       Impact factor: 3.619

Review 4.  Polycystic ovary syndrome: is the cardiometabolic risk increased after menopause?

Authors:  Snigdha Alur-Gupta; Anuja Dokras
Journal:  Menopause       Date:  2019-03       Impact factor: 2.953

Review 5.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

Authors: 
Journal:  Hum Reprod       Date:  2004-01       Impact factor: 6.918

6.  Decreased androgen levels and improved menstrual pattern after angiotensin II receptor antagonist telmisartan treatment in four hypertensive patients with polycystic ovary syndrome: case series.

Authors:  Mojca Jensterle; Andrej Janez; Bojan Vrtovec; Helena Meden-Vrtovec; Marija Pfeifer; Janez Prezelj; Tomaz Kocjan
Journal:  Croat Med J       Date:  2007-12       Impact factor: 1.351

7.  Pregnancy Complications and Later Development of Hypertension.

Authors:  Suttira Intapad; Barbara T Alexander
Journal:  Curr Cardiovasc Risk Rep       Date:  2013-06-01

8.  Fecundity among women with polycystic ovary syndrome (PCOS)-a population-based study.

Authors:  S Persson; E Elenis; S Turkmen; M S Kramer; E-L Yong; I Sundström-Poromaa
Journal:  Hum Reprod       Date:  2019-10-02       Impact factor: 6.918

9.  Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Fahimeh Ramezani Tehrani; Mina Amiri; Samira Behboudi-Gandevani; Razieh Bidhendi-Yarandi; Enrico Carmina
Journal:  Gynecol Endocrinol       Date:  2019-08-06       Impact factor: 2.260

Review 10.  Blood pressure in postmenopausal women with a history of polycystic ovary syndrome.

Authors:  Katarzyna Doroszewska; Tomasz Milewicz; Sandra Mrozińska; Jarosław Janeczko; Radosław Rokicki; Marek Janeczko; Damian Warzecha; Piotr Marianowski
Journal:  Prz Menopauzalny       Date:  2019-06-14
View more
  5 in total

1.  Consequences of hyperandrogenemia during pregnancy in female offspring: attenuated response to angiotensin II.

Authors:  Noha M Shawky; Carolina Dalmasso; Norma B Ojeda; Yvonne Zuchowski; Nina Stachenfeld; Barbara T Alexander; Jane F Reckelhoff
Journal:  J Hypertens       Date:  2022-04-01       Impact factor: 4.844

Review 2.  Polycystic Ovary Syndrome: Insights from Preclinical Research.

Authors:  Jane F Reckelhoff; Noha M Shawky; Damian G Romero; Licy L Yanes Cardozo
Journal:  Kidney360       Date:  2022-06-17

3.  Effect of free androgen index on blood pressure variability and target organ damage in postmenopausal hypertensive women: findings from a cross-sectional study.

Authors:  Jianshu Chen; Qiongying Wang; Ying Pei; Ningyin Li; Junchen Han; Jing Yu
Journal:  Menopause       Date:  2021-08-23       Impact factor: 3.310

4.  Cardiometabolic consequences of maternal hyperandrogenemia in male offspring.

Authors:  Yvonne Zuchowski; Carolina Dalmasso; Noha M Shawky; Jane F Reckelhoff
Journal:  Physiol Rep       Date:  2021-07

5.  mTOR inhibitor improves testosterone-induced myocardial hypertrophy in hypertensive rats.

Authors:  Jianshu Chen; Jing Yu; Ruowen Yuan; Ningyin Li; Caie Li; Xiaofang Zhang
Journal:  J Endocrinol       Date:  2022-01-31       Impact factor: 4.286

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.